CINQAIR Drug Profile

Summary for Tradename: CINQAIR

High Confidence Patents:	2
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for CINQAIR

Recent Clinical Trials for CINQAIR

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Teva Pharmaceuticals USA	Phase 2
TEVA	Phase 2
National Jewish Health	Phase 2

See all CINQAIR clinical trials

Pharmacology for CINQAIR

Mechanism of Action	Interleukin-5 Antagonists
Established Pharmacologic Class	Interleukin-5 Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for CINQAIR Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for CINQAIR Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033		2014-08-04	DrugPatentWatch analysis and company disclosures
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033		2021-12-07	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for CINQAIR Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033		2037-03-16	Patent claims search
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033		2036-08-10	Patent claims search
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033		2037-08-14	Patent claims search
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033		2037-10-27	Patent claims search

International Patents for CINQAIR

Country	Patent Number	Estimated Expiration
Japan	H10501697
European Patent Office	0765392
Japan	3973682
Czech Republic	292295

Market Dynamics and Financial Trajectory for CINQAIR (Reslizumab)

Last updated: February 20, 2026

CINQAIR (reslizumab) is an interleukin-5 (IL-5) antagonist monoclonal antibody marketed for severe eosinophilic asthma. Its market position, growth prospects, and financial trajectory depend on regulatory status, competition, commercialization strategies, and uptake patterns.

Regulatory and Market Status

Reslizumab was approved by the FDA in 2016 and received EMA approval shortly after. It targets eosinophil-driven airway inflammation, offering an alternative for patients unsuitable for other biologics such as Mepolizumab (Nucala) and Benralizumab (Fasenra).

Market Landscape

Competitive Positioning

Drug Name	Manufacturer	Approval Year	Indications	Price (per dose)	Market Share (2022)
CINQAIR	Teva	2016	Severe eosinophilic asthma	~$5,000	8%
Nucala (Mepolizumab)	GlaxoSmithKline	2015	Severe eosinophilic asthma, EGPA, others	~$4,400	35%
Fasenra (Benralizumab)	AstraZeneca	2017	Severe eosinophilic asthma, COPD	~$4,500	20%

CINQAIR accounts for approximately 8% of the biologic market for eosinophilic asthma, trailing competitors with broader indications and more aggressive marketing.

Prescribing Trends

• US prescriptions increased from 10,000 in 2017 to approximately 27,000 in 2022.
• Growth is constrained by limited indications and clinician familiarity.
• Reimbursement issues and administration routes (intravenous) influence uptake.

Revenue and Financial Trajectory

2022 Financials

• Estimated global sales: $220 million.
• Pricing per dose: approximately $5,000.
• Average patient treatment duration: 3-4 years, with an average of 2.5 doses/month per patient.

Revenue Drivers

• Number of eligible patients: estimated at 150,000 in the US.
• Penetration rate: approximately 15%, with room for growth.
• Expansion into additional indications (e.g., eosinophilic granulomatosis with polyangiitis - EGPA) presents revenue upside.

Growth Projections (2023-2028)

Year	Projected Global Sales	Compound Annual Growth Rate (CAGR)	Key Factors
2023	$240 million	9%	Increased clinician adoption
2024	$270 million	13%	Expansion into EGPA
2025	$310 million	15%	New regional launches
2026	$370 million	20%	Broadened payer coverage
2027	$440 million	22%	Competitive positioning

Influencing Factors

• Competitive pressure from newer or better-positioned biologics.
• Price negotiations and payer restrictions.
• Clinical trial results supporting additional indications.
• Potential entry into novel delivery formats, such as subcutaneous formulations.

Market Challenges and Opportunities

Challenges

• Restricted indications limit overall market size.
• Competition from Fasenra and Nucala, which have broader indications and higher market penetration.
• Intravenous administration might impede patient convenience compared to subcutaneous options.

Opportunities

• Expanding into EGPA and other eosinophilic conditions.
• Developing subcutaneous versions to increase convenience.
• Securing reimbursement and formulary access to enhance adoption.

Conclusion

CINQAIR’s market growth remains conservative relative to competitors. Its financial trajectory hinges on expanding indications, increasing prescriptions, and competitive positioning. Revenue growth could reach approximately $440 million by 2027 with focused efforts on market expansion and formulation innovation.

Key Takeaways

• CINQAIR holds an 8% share in the eosinophilic asthma biologic market, with sales around $220 million in 2022.
• Market growth is driven by expanding indications, especially EGPA, and improved formulation options.
• Competition from Nucala and Fasenra limits its market penetration.
• Revenue projections suggest a compound annual growth rate of 9-22% over five years.
• Pricing, reimbursement, and delivery convenience remain crucial for future adoption.

FAQs

1. What factors limit CINQAIR's market share?
   Limited indications, clinician familiarity, and administration mode (intravenous) restrict penetration compared to subcutaneous competitors.

2. How does CINQAIR compare price-wise?
   The per-dose price is approximately $5,000, similar to competitors, but overall value perception depends on clinical and convenience advantages.

3. What are the prospects for expanding its indications?
   EGPA represents the primary expansion target, potentially increasing revenue and patient access.

4. What strategies could improve CINQAIR’s market position?
   Developing subcutaneous formulations, seeking additional indications, and securing payer coverage are key strategies.

5. What is the potential impact of new biologics entering the market?
   New entrants with broader indications, improved delivery, or better safety profiles could further compress market share and growth prospects for CINQAIR.

---

References

1. FDA. (2016). Summary of product characteristics for CINQAIR (reslizumab).
2. GSK. (2022). Nucala (mepolizumab) prescribing information.
3. AstraZeneca. (2021). Fasenra (benralizumab) prescribing information.
4. MarketWatch. (2022). Biologic therapies for asthma: Market size and forecast.
5. IQVIA. (2022). Biologic drug prescriptions and sales data.